 |
市場調査レポート
二重特異性抗体の世界市場：市場機会、医薬品の売上高、治験の考察 (2026年)Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026 |
||||||
| 発行 | KuicK Research | 商品コード | 923628 | ||||
| 出版日 | ページ情報 | 英文 510 Pages 納期: 即日から翌営業日 |
|||||
| 価格 |
|
||||||
| 二重特異性抗体の世界市場：市場機会、医薬品の売上高、治験の考察 (2026年) Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026 | ||
| 出版日: 2020年02月03日 | ページ情報: 英文 510 Pages |
|
二重特異性抗体は2015年に上市されてから世界各国で順調に売上高を伸ばしており、2019年までに118％のCAGRで成長してきました。短期的な販売目標の達成だけでなく、次世代の抗体療法としての地位も着々と構築しつつあります。
当レポートでは、世界の二重特異性抗体の市場について分析し、二重特異性抗体の概要や診断・治療上の主な効果、現在開発中・治験中のパイプライン製品の概略、主な市場促進・抑制要因、全体的な市場規模の動向見通し、カテゴリー別の市場規模・価格動向の見通し、今後の市場機会などを調査しております。
"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:
“Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global bispecific antibodies market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on two (Blincyto & Hemlibra) commercially available bispecific antibodies with their regional level revenue, market share and the clinical profile.
"Since Commercially Launch In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019"
The availability of the bispecific antibodies in the market and the revenue generated by the drugs in short span of four years (since commercialization in 2015) clearly depicts the current dominant trends followed by its characterization as a next generation of antibody therapy. The number of the investigational agents under preclinical and clinical trials all around the globe adds as a major key component for the establishment of the antibody therapy as a one stop treatment for all the disease.
Pharmaceutical companies involved in the development of these promising bispecific antibodies molecules strongly believe that their products are superior to first generation nonspecific antibody products. No doubt they are adamant to their viewpoint that bispecific antibodies will be more potent against disease targets, which includes combating more than one aspect of the disease simultaneously, better and cheaper production with least side effects. The molecules are also said to have the potential of dealing with multiple disease with a single agent making them more important.
“Structural Diversity Among The Antibodies Are Opening A Wide Plethora For The Novel Bispecific Antibody Agents, And Thus Providing A Great Opportunity For Establishing A Superior Market In The Future.”
Bispecific antibodies are not only being developed for the oncological use but also the non oncological which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. Their vitality if approved can also make them a great tool in the diagnostics tests detect and monitor infectious agents like HIV, the cause of AIDS, or the influenza virus causing pandemic flu and for identifying diseases released by biological weapons such as smallpox and anthrax. In addition, monoclonal antibodies have also helped in checks for salmonella and bacteria that cause food poisoning. The global opportunity value of the bispecific antibody market is estimated to be approximately US$ 10 billion per year, which is expected to be achieved in next five year timeframe.
